Mario Campone

Summary

Publications

  1. pmc γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
    Céline Séveno
    Team 8 Cell survival and tumor escape in breast cancer, UMR 892 INSERM 6299 CNRS Université de Nantes, Institut de Recherche Thérapeutique de l Université de Nantes, 8, quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France
    Breast Cancer Res 14:R96. 2012
  2. doi request reprint Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study
    Mario Campone
    institut de cancérologie de l Ouest René Gauducheau, Centre de Recherche en Cancerologie, Boulevard Jacques Monod, 44805 Saint Herblain Nantes cedex, France
    Eur J Cancer 49:2621-32. 2013
  3. doi request reprint A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines
    Mario Campone
    institut de cancérologie de l Ouest René Gauducheau, Centre de Recherche en Cancerologie, UMR INSERM 892, St Herblain, France
    Breast J 19:240-9. 2013
  4. doi request reprint A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    M Campone
    Centre Rene Gauducheau, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 69:871-9. 2012
  5. doi request reprint Eribulin mesylate for the treatment of late-stage breast cancer
    Carole Gourmelon
    Institut du Cancer de l Ouest Centre René Gauducheau, bd Jacques Monod, 44805 Saint Herblain, France
    Expert Opin Pharmacother 12:2883-90. 2011
  6. doi request reprint [Tumor resistance to HER2 inhibitors: the drug sedimentation concept]
    Mario Campone
    Centre Rene Gauducheau, Departement d Oncologie Medicale, Boulevard Jacques Monod, 44805 Saint Herblain, Nantes Cedex, France
    Bull Cancer 99:665-72. 2012
  7. ncbi request reprint Taxanes in adjuvant breast cancer setting: which standard in Europe?
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44 805 Nantes Cedex Saint Herblain, France
    Crit Rev Oncol Hematol 55:167-75. 2005
  8. ncbi request reprint [Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France
    Bull Cancer 90:614-22. 2003
  9. ncbi request reprint Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study
    Mario Campone
    Centre Rene Gauducheau, 44805 Nantes St Herblain, France
    Breast 15:601-9. 2006
  10. ncbi request reprint Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
    Mario Campone
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 60:523-33. 2007

Collaborators

Detail Information

Publications22

  1. pmc γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
    Céline Séveno
    Team 8 Cell survival and tumor escape in breast cancer, UMR 892 INSERM 6299 CNRS Université de Nantes, Institut de Recherche Thérapeutique de l Université de Nantes, 8, quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France
    Breast Cancer Res 14:R96. 2012
    ..In this study, we thus specifically addressed the biologic consequences of targeting γ-secretase and Bcl-2/Bcl-xL, alone or simultaneously, in breast cancer cell lines as well as in a novel human breast cancer ex vivo assay...
  2. doi request reprint Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study
    Mario Campone
    institut de cancérologie de l Ouest René Gauducheau, Centre de Recherche en Cancerologie, Boulevard Jacques Monod, 44805 Saint Herblain Nantes cedex, France
    Eur J Cancer 49:2621-32. 2013
    ..1 months, respectively) central assessment in postmenopausal women with HR(+), HER2(-) ABC recurring/progressing during/after NSAI therapy. The BOLERO-2 trial included a substantial proportion of patients with visceral metastases (56%)...
  3. doi request reprint A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines
    Mario Campone
    institut de cancérologie de l Ouest René Gauducheau, Centre de Recherche en Cancerologie, UMR INSERM 892, St Herblain, France
    Breast J 19:240-9. 2013
    ....
  4. doi request reprint A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    M Campone
    Centre Rene Gauducheau, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 69:871-9. 2012
    ....
  5. doi request reprint Eribulin mesylate for the treatment of late-stage breast cancer
    Carole Gourmelon
    Institut du Cancer de l Ouest Centre René Gauducheau, bd Jacques Monod, 44805 Saint Herblain, France
    Expert Opin Pharmacother 12:2883-90. 2011
    ..1 versus 10.6 months HR 0.81, p = 0.041). This compound is well tolerated. The most common adverse event is neutropenia...
  6. doi request reprint [Tumor resistance to HER2 inhibitors: the drug sedimentation concept]
    Mario Campone
    Centre Rene Gauducheau, Departement d Oncologie Medicale, Boulevard Jacques Monod, 44805 Saint Herblain, Nantes Cedex, France
    Bull Cancer 99:665-72. 2012
    ....
  7. ncbi request reprint Taxanes in adjuvant breast cancer setting: which standard in Europe?
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44 805 Nantes Cedex Saint Herblain, France
    Crit Rev Oncol Hematol 55:167-75. 2005
    ..remain unanswered, including whether the use of taxanes should be sequential or concomitant, and which population would benefit from such a treatment: patients with hormone-receptor negative disease and/or the HER-2 positive tumors?..
  8. ncbi request reprint [Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France
    Bull Cancer 90:614-22. 2003
    ..This antibody demonstrated a significant activity in clinical trials. In this review, we discuss the preclinical (mechanisms of action) and clinical data with the combination of trastuzumab and taxanes...
  9. ncbi request reprint Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study
    Mario Campone
    Centre Rene Gauducheau, 44805 Nantes St Herblain, France
    Breast 15:601-9. 2006
    ..5 months; median time to progression 8.4 months; and median time to treatment failure 4.8 months. Gemcitabine and epirubicin are well tolerated and active in MBC patients, and the group B regimen warrants further investigation...
  10. ncbi request reprint Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
    Mario Campone
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 60:523-33. 2007
    ..To determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compound, in advanced solid tumor patients...
  11. ncbi request reprint [Her2 positive breast cancer: practices]
    Mario Campone
    Institut du cancer Nantes Atlantiques, Centre Rene Gauducheau, Saint Herblain, France
    Bull Cancer 98:154-63. 2011
    ..This literature review aims to make the data points on pertinent and useful data for physicians in daily...
  12. doi request reprint Vinflunine: a new microtubule inhibitor agent
    Jaafar Bennouna
    Centre Rene Gauducheau, Saint Herblain, France
    Clin Cancer Res 14:1625-32. 2008
    ..The efficacy of vinflunine in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen was confirmed by a large phase III trial...
  13. ncbi request reprint Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer
    Mario Campone
    Centre Rene Gauducheau, Service Oncologie Medicale, Boulevard Jacques Monod, 44805, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 63:937-43. 2009
    ..In an effort to improve patient convenience, we investigated in first-line treatment a regimen alternating i.v. and oral vinorelbine in combination with docetaxel...
  14. ncbi request reprint [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]
    Mario Campone
    CRLCC, Centre Rene Gauducheau, bd Jacques Monod, 44805 Saint Herblain Nantes
    Bull Cancer 90:851-64. 2003
    ..In this review, we describe the different pathways implicated in the transduction of signal and the potential target for new agents in breast cancer...
  15. doi request reprint Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
    Mario Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Boulevard Jacques Monod, Nantes Saint Herblain, France
    Crit Rev Oncol Hematol 78:195-205. 2011
    ....
  16. ncbi request reprint [Cardiac dysfunction induced by trastuzumab]
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 NANTES Cedex
    Bull Cancer 91:166-73. 2004
    ..We discuss in this article the incidence, the physiopathology, the risk factors, the predictive factors and the patient management and on cardiotoxicity of trastuzumab...
  17. ncbi request reprint Vinflunine: a novel antitubulin agent in solid malignancies
    Jaafar Bennouna
    Centre Rene Gauducheau, Saint Herblain, France
    Expert Opin Investig Drugs 14:1259-67. 2005
    ..Clinically significant activity was seen in the Phase II studies for the treatment of bladder, non-small cell lung and breast cancers, thus prompting the initiation of the Phase III trials that are currently ongoing...
  18. doi request reprint Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence
    Christine Bobin-Dubigeon
    institut de cancérologie de l Ouest, Centre Rene Gauducheau, Nantes, France
    Clin Biochem 45:1503-5. 2012
    ..To relate paraoxonase (PON1) activity to survival time and short term death in breast cancer recurrence...
  19. doi request reprint What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?
    Carole Gourmelon
    Institut du Cancer de l Ouest Centre René Gauducheau, bd Jacques Monod, 44805 Saint Herblain, France
    Expert Rev Anticancer Ther 12:195-201. 2012
    ..The aim of this article is to describe chemotherapy-trastuzumab combinations that have been evaluated in patients with HER2-positive metastatic breast cancer, and to define the possible standards and options...
  20. ncbi request reprint [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]
    Mario Campone
    Service d Oncologie, Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain Cedex
    Bull Cancer 89:275-82. 2002
    ..Weekly administration of paclitaxel which is generally well tolerated increases the therapeutic index (efficacy/safety) resulting from anti-angiogenic and pro-apoptotic effects...
  21. doi request reprint Decoding and unlocking the BCL-2 dependency of cancer cells
    Philippe Juin
    Team 8 Cell survival and tumor escape in breast cancer, UMR 892 INSERM 6299 CNRS Université de Nantes, Institut de Recherche Thérapeutique de l Université de Nantes, 8 quai Moncousu, BP 70721, 44007 NANTES Cedex, 1 France
    Nat Rev Cancer 13:455-65. 2013
    ....
  22. doi request reprint Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study
    Pascal Jezequel
    Département de Biologie Oncologique, institut de cancérologie de l Ouest René Gauducheau, Bd J Monod, Nantes Saint Herblain Cedex, France
    Int J Cancer 131:426-37. 2012
    ..We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM...